Test Price
2,800 AED✅ Home Collection Available
XYLT1 Gene Desbuquois Dysplasia Type 2 Genetic Test in UAE – 2800 AED – DHA Licensed Molecular Diagnostics
Executive Summary & Core Metrics
Diagnostic Confidence & Service Highlights
- Accuracy Guarantee: 99.9% analytical sensitivity and specificity via ISO-accredited next-generation sequencing (NGS) full-gene analysis.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all UAE emirates.
- Clinical Guidance: Telephonic post-test clinical guidance provided by a Consultant Medical Geneticist for result interpretation and family counselling.
- Insurance & Billing: Direct billing verification supported via WhatsApp at +971 54 548 8731.
Key Metrics at a Glance
- Price: 2,800 AED (all-inclusive, no hidden fees).
- Turnaround Time: 21–28 calendar days (3–4 weeks) from sample receipt.
- Sample Type: Peripheral whole blood, FTA card dried blood spot, or previously extracted genomic DNA.
- Regulatory Oversight: DHA-licensed facility (License No. 1143) operating under UAE Federal Decree-Law No. 45 of 2021 (PDPL).
Test Overview & Methodology
This molecular diagnostic assay employs clinical-grade next-generation sequencing (NGS) to interrogate the entire coding region and conserved splice sites of the XYLT1 gene. The test is indicated for individuals with clinical and radiographic suspicion of Desbuquois dysplasia type 2, a rare autosomal recessive skeletal disorder characterised by short stature, joint laxity, distinctive facial features, and advanced bone age. Definitive genetic confirmation enables precise medical management, accurate recurrence risk counselling, and informed family planning decisions.
| Feature | Our Test – NGS Full Gene Sequencing | Closest Alternative – Sanger Sequencing |
|---|---|---|
| Analytical Precision | 99.9% sensitivity and specificity across all coding exons and flanking intronic regions. | ~95% detection rate; limited to pre-selected exons and known hotspots. |
| Methodology | LC-MS/MS adapted NGS library preparation with paired-end 150 bp reads; minimum 50× depth at all target bases. | Bidirectional Sanger sequencing of individually amplified exons. |
| Turnaround Time | 3–4 weeks (comprehensive clinical report with variant interpretation per ACMG guidelines). | 6–8 weeks (iterative rounds required if initial targets are negative). |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I recognise the profound anxiety that accompanies a suspected diagnosis of a rare skeletal dysplasia. Early, definitive genetic confirmation through XYLT1 gene sequencing empowers families with accurate prognostic information, guides surveillance for associated complications, and enables informed reproductive choices. I strongly emphasise that this molecular result must be interpreted in the context of full clinical, radiographic, and multidisciplinary specialist evaluation to ensure holistic patient care.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Advisory
⚠ Important Clinical Precaution
Do not discontinue, alter, or initiate any prescribed medication or therapy based solely on genetic test results without direct consultation with the treating physician. Genetic findings require correlation with clinical presentation and may necessitate specialist referral for metabolic bone disease management.
Safety Exclusion Criteria & Red Flags
- This test is not intended for asymptomatic individuals without clinical or radiographic suspicion of Desbuquois dysplasia type 2; pre-test genetic counselling by a qualified genetics professional is mandatory.
- This assay is not designed for emergency or acute diagnostic scenarios. A child presenting with stridor, acute respiratory compromise, cyanosis, or sudden neurological deterioration requires immediate emergency medical evaluation and stabilisation before any genetic testing is considered.
- If severe spinal malformation, cervical instability, or airway compromise is suspected, urgent radiological assessment (MRI/CT) and paediatric orthopaedic or neurosurgical consultation must take precedence over molecular testing.
Patient FAQ & Clinical Guidance
1. What is the purpose of the XYLT1 gene test?
This test identifies pathogenic variants in the XYLT1 gene that cause Desbuquois dysplasia type 2, a rare congenital skeletal disorder inherited in an autosomal recessive pattern. Confirming the genetic aetiology allows clinicians to implement targeted surveillance for complications such as spinal instability, joint dislocations, and respiratory compromise, and provides families with accurate recurrence risk information for future pregnancies (25% risk per pregnancy when both parents are carriers).
2. How is the test sample collected?
The test requires one of the following specimen types: a standard peripheral whole blood sample (2–5 mL in an EDTA tube), a dried blood spot on a Whatman FTA card (3–5 drops), or previously extracted genomic DNA of adequate quality and quantity. Our DHA-licensed phlebotomists provide a VIP mobile home collection service across all UAE emirates, operating daily from 8 AM to 11 PM, using temperature-controlled cold-chain transport to preserve nucleic acid integrity.
3. How long do results take and what is the cost?
Results are delivered within 21–28 calendar days (3–4 weeks) from the date of sample receipt in the laboratory. The all-inclusive cost is 2,800 AED, covering sample collection, NGS analysis, bioinformatic interpretation, and a comprehensive clinical report. Telephonic post-test guidance by a Consultant Medical Geneticist is included. Direct insurance billing verification is available via WhatsApp at +971 54 548 8731.
4. Who should consider this genetic test?
This test is indicated for individuals with clinical and radiographic features suggestive of Desbuquois dysplasia type 2, including pre- and post-natal short stature, joint hypermobility, advanced carpal bone age, characteristic facial dysmorphism, and spinal abnormalities. It is also appropriate for at-risk family members (siblings of an affected individual) and for couples with a known family history who are seeking reproductive risk assessment. Pre-test genetic counselling is strongly recommended.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance Framework
- Data Protection: All patient genetic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring lawful collection, processing, and retention of sensitive health information.
- Health Information Governance: The laboratory adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, governing the secure electronic handling of clinical records and genetic test results.
- Medical Liability & Patient Safety: Clinical genetic testing and patient consent procedures follow the standards established under Federal Decree-Law No. 4 of 2016 on Medical Liability, ensuring accountability and patient rights protection throughout the diagnostic pathway.
- Facility Licensing: DNA Labs UAE operates under DHA Facility License Number 1143, with laboratory premises located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. The laboratory holds ISO 9001:2015 certification (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | XYLT1 Gene Desbuquois Dysplasia Type 2 Genetic Test (NGS Full Gene Sequencing) |
| Price (AED) | 2,800 AED (all-inclusive, no additional charges) |
| Turnaround Time | 21–28 calendar days (3–4 weeks) from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA), FTA card dried blood spot, or extracted genomic DNA |
| Methodology Used | Next-Generation Sequencing (NGS) – LC-MS/MS adapted library preparation, paired-end 150 bp reads, full exon and splice-site coverage, minimum 50× depth |
| ICD-10-CM Code | Q77.8 (Other osteochondrodysplasias) |
| LOINC Code | 81260-5 (DNA sequence analysis) |
| DHA Facility License & Laboratory Address | DHA License No. 1143 – DNA Labs UAE – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians